# Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.

Source: https://onco.cc/trials/nct06600022/  
OnCo record `nct06600022` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SCTB41 in advanced solid tumours, run by Sinocelltech Ltd., now recruiting.

## Summary

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. is a phase 1/2 interventional study registered as NCT06600022 by Sinocelltech Ltd., with 441 participants planned, started 2024-10-10 and due to reach its primary completion in 2027-04-30. Interventions recorded: SCTB41.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06600022
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB41 in Patients with Advanced Malignant Solid Tumours
- Sponsor: Sinocelltech Ltd.
- Enrolled: 441

## Sources

- ClinicalTrials.gov NCT06600022: https://clinicaltrials.gov/study/NCT06600022

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [SCTB41](https://onco.cc/drugs/sctb41/)
- companies: [Sinocelltech](https://onco.cc/companies/sinocelltech/)

---
JSON: https://onco.cc/api/v1/entities/nct06600022.json